Optimizing Outcomes in Hypoparathyroidism: A New Era in Treatment Approaches

4 experts are featured in this series.

Welcome back to another HCPLive Peer Exchange series. In this opening episode, panelists highlight the underlying causes of hypoparathyroidism and the impact of the loss of parathyroid hormone function by examining the following critical questions: 1. What is chronic hypoparathyroidism, and how is it defined? 2. How does the loss of parathyroid hormone (PTH) function disrupt calcium and phosphate homeostasis in hypoparathyroidism? 3. What are the causes of chronic hypoparathyroidism, and is there any way to predict or prevent it? When might genetic testing be appropriate? In the next episode, panelists will continue their discussion on hypoparathyroidism and highlight how it is diagnosed and the key challenges in the diagnosis and monitoring of patients with hypoparathyroidism.

4 experts are featured in this series.

In this episode, ‘Hypoparathyroidism Diagnosis and Challenges,’ the panelists explore how hypoparathyroidism is diagnosed as well as key diagnostic and monitoring challenges that clinicians face. Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 1. How is hypoparathyroidism diagnosed? 2. What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward. The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

4 experts are featured in this series.

In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients. Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 1. How is hypoparathyroidism diagnosed? 2. What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward. The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.

4 experts are featured in this series.

This episode, titled ‘Evaluating the Efficacy and Safety of Palopegteriparatide in Hypoparathyroidism from the PaTHway Trial,’ features panelists discussing the efficacy and safety data of palopegteriparatide in hypoparathyroidism from the phase 3 PaTHway trial as well as the limitations of the trial.

4 experts are featured in this series.

In ‘Safety and Titration Considerations and Quality of Life Impact of PTH-Based Therapy in Hypoparathyroidism,’ our panel delves into the potential titration challenges, safety considerations, and long-term monitoring of PTH-based therapy in patients with hypoparathyroidism. They also discuss the impact of PTH-based therapy on patient quality of life.

4 experts are featured in this series.

In this episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism,’ the experts explore the importance of recommending medical advocates or medical alerts to patients as well as educational resources that are available for community providers to better manage hypoparathyroidism.